350
Participants
Start Date
August 31, 2023
Primary Completion Date
December 31, 2024
Study Completion Date
October 31, 2028
Olverembatinib
Orally, once every other day (QOD).
Imatinib
Orally, once daily (QD).
RECRUITING
Alfred Health, Melbourne
RECRUITING
Royal Adelaide Hospital, Adelaide
RECRUITING
Royal Perth Hospital, Perth
NOT_YET_RECRUITING
Shanghai Jiao Tong University School of Medicine Ruijin Hospital, Shanghai
NOT_YET_RECRUITING
Xinqiao Hospital of Army Medical University, Chongqing
RECRUITING
The first affiliated hospital of Suzhou University, Suzhou
NOT_YET_RECRUITING
Institute of blood transfusion of Chinese Academy of Medical Sciences, Tianjin
NOT_YET_RECRUITING
The First Affiliated Hospitalo of Bengbu Medical School, Bengbu
NOT_YET_RECRUITING
Wuhan Union Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan
NOT_YET_RECRUITING
Henan Cancer Hospital, Zhengzhou
NOT_YET_RECRUITING
Guangdong Province People's Hospital, Guangdong
NOT_YET_RECRUITING
Nanfang Hospital of Southern Medical University, Guangdong
NOT_YET_RECRUITING
West China Hospital of Sichuan University, Chengdu
RECRUITING
Royal North Shore Hospital, St Leonards
Lead Sponsor
HealthQuest Pharma Inc.
INDUSTRY
Ascentage Pharma Group Inc.
INDUSTRY